AI Article Synopsis
- The increasing popularity of GLP-1 receptor agonists and iSGLT2 aligns with new guidelines from cardiology, nephrology, and diabetology societies.
- Despite their potential benefits, caution is advised, especially for the very elderly and frail, due to a lack of scientific research on these populations.
- A thorough geriatric assessment is necessary before starting treatment with these medications.
Article Abstract
The use of GLP-1 receptor agonists and iSGLT2 is becoming increasingly common, in line with new guidelines issued by the learned societies of cardiology, nephrology and diabetology. However, the enthusiasm aroused by these new drugs needs to be tempered and their use in the very elderly and/or frail needs to be carefully considered by the lack of scientific studies in this population category, , and their prescription requires a comprehensive geriatric assessment before initiating this type of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2024.20.893.1983 | DOI Listing |
Publication Analysis
Top Keywords
glp-1 receptor
8
receptor agonists
8
agonists isglt2
8
[prescription glp-1
4
isglt2 geriatrics
4
geriatrics risk?]
4
risk?] glp-1
4
isglt2 increasingly
4
increasingly common
4
common guidelines
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!